← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › BACTERIAL AND VIRAL VACCINES, COMBINED › Bacterial and viral vaccines, combined
diphtheria-pertussis-poliomyelitis-tetanus
J07CA02
Forms & Strengths
- Diphtheria toxoid 2-5 Lf units
- Pertussis toxoid 2-5 Lf units
- Poliomyelitis (Inactivated) 40-80 D-antigen units, type 1
- Poliomyelitis (Inactivated) 8-16 D-antigen units, type 2
- Poliomyelitis (Inactivated) 32-64 D-antigen units, type 3
- Tetanus toxoid 5-20 Lf units
- Combination with Haemophilus influenzae type b conjugate vaccine
- Combination with Hepatitis B vaccine
Adult Dosing
- 0.5 mL intramuscularly as a booster dose every 10 years
- For individuals with incomplete schedule: 2-3 doses, 4-6 weeks apart
- For travel to high-risk areas: booster dose if last dose was more than 10 years ago
Pediatric Dosing
- Primary series: 3 doses at 2, 4, and 6-12 months of age
- Booster dose at 12-18 months, and every 10 years thereafter
- First booster can be given as early as 12 months after completion of primary series
Indications
- Prevention of diphtheria
- Prevention of pertussis
- Prevention of poliomyelitis
- Prevention of tetanus
Mechanism of Action
- Stimulation of active immunity to diphtheria, pertussis, poliomyelitis, and tetanus toxins
- Induction of antibody production and immune memory
Contraindications
- Hypersensitivity to any component of the vaccine
- History of severe allergic reaction to previous dose
- Encephalopathy within 7 days of previous pertussis-containing vaccine
Adverse Reactions
- Local reactions: redness, swelling, pain at injection site
- Systemic reactions: fever, headache, fatigue
- Allergic reactions: anaphylaxis, urticaria, angioedema
Drug Interactions
- Concomitant administration with other vaccines may increase risk of adverse reactions
- Immunosuppressive therapy may reduce efficacy of vaccine
- Corticosteroids may interfere with immune response to vaccine
Curated Content: Needs Vetting Before Put to Clinical Use